Biotechnology
Australian biotech Immutep’s shares plummeted 88.6% to A$0.045 today, after it announced that the Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa (efti) in patients in first-line non-small cell lung cancer (NSCLC) has recommended the discontinuation of the trial following a planned interim futility analysis in accordance with the study protocol. 13 March 2026
Pharmaceutical
Eli Lilly has announced plans to invest a total of $3 billion over the next 10 years to comprehensively expand its supply chain capacity in China. 12 March 2026
Biosimilars
Costa Rica-based specialty healthcare company SteinCares has signed a licensing agreement with India’s Shilpa Biologicals, part of Shilpa Medicare, to commercialize a biosimilar across Latin America. 11 March 2026
Biosimilars
The US Food and Drug Administration (FDA) has released New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 4). 10 March 2026
Pharmaceutical
The US Food and Drug Administration (FDA) has approved pharma major Bristol Myers Squibb’s Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis (PsA). Sotyktu, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, is the first TYK2 inhibitor to be approved for PsA. 9 March 2026
Most Read
Features
Company Spotlight
A clinical-stage biotechnology company developing first-in-class therapies aimed at overcoming tumor immune evasion and drug resistance. Purple Biotech focuses on immuno-oncology and targeted cancer therapies designed to enhance immune responses against solid tumors.
Recent news
Pharmaceutical
Days after announcing an exclusive licensing and supply agreement with South Korean pharma company Ahngook Pharmaceutical, George Medicines has announced another deal relating to GMRx2. 16 March 2026
Pharmaceutical
Sentynl Therapeutics, a USA-based biopharma and wholly-owned subsidiary of India’s Zydus Lifesciences, has announced a deal with Korean rare genetic diseases specialist PRG S&T to license its investigational molecule progerinin (SLC-D011) for Hutchinson-Gilford progeria syndrome (HGPS). 16 March 2026
Generics
The escalating conflict in the Middle East has moved beyond oil markets and energy security to strike at one of India’s most globally integrated industries: pharmaceuticals. 16 March 2026
Biotechnology
Shares of US biotech CytomX Therapeutics’ rocketed 53% to $7.16, after the leader in the field of masked, conditionally activated biologics, today announced positive Phase I expansion data for its EpCAM PROBODY ADC, varsetatug masetecan (Varseta-M) in late-line metastatic CRC. 16 March 2026
Pharmaceutical
Sovereign wealth funds once appeared only intermittently in life-science financing. Their money surfaced through venture funds or private equity partnerships, usually at one remove from the operating companies themselves. Over the past decade that distance has narrowed, particularly as Gulf investors have become more comfortable deploying capital directly. 16 March 2026
Refine search
In Brief
Biotechnology
9 March 2026 Swiss contract development and manufacturing organizations (CDMO) Sandoz and Genetix Biotherapeutics, a commercial-stage biotechnology company dedicated to delivering genetic therapies for patients with severe rare diseases, today announced the extension of their long-term commercial manufacturing agreement.
Pharmaceutical
25 February 2026 KDventures has revealed that the planned reversed acquisition of the portfolio company SVF Vaccines by Novakand Pharma will not be completed, following Nasdaq’s rejection of an application for continued listing of the combined entity.
Conferences
23 February 2026 26 February 2026 London, UK, ExCeL London
18 March 2026 19 March 2026 London, UK
23 March 2026 25 March 2026 Lisbon, Portugal, FIL – Lisbon Exhibition and Congress Centre
23 March 2026 24 March 2026 Virginia, USA, Hyatt Regency Crystal City
24 March 2026 26 March 2026 Madrid, Spain, IFEMA MADRID
24 March 2026 26 March 2026 Dubai, UAE, Dubai World Trade Center
Insights
Biotechnology
This week on The Pharma Letter Podcast, we’re joined by Eron Kelly, chief executive of ConcertAI: a company applying artificial intelligence to accelerate oncology research and clinical development. 13 March 2026
Pharmaceutical
For years, AI in pharma largely remained in the innovation phase. Companies ran pilot programs, formed partnerships and showcased demonstrations, but there was limited impact on how organizations were structured, how teams worked or how decisions were made. 11 March 2026
Pharmaceutical
Russia is facing a new wave of drug shortages this year, as local media reported about the lack of supplies of anti-epilepsy drug for children, The Pharma Letter’s local correspondent reports. 11 March 2026
Biosimilars
Russian drugmaker Biocad risks losing the market for its anti-cancer drug pertuzumab, where it expanded in 2025. This is due to recent submitting a lawsuit against the company by Swiss pharma giant Roche for patent infringement of branded Perjeta, reports The Pharma Letter’s local correspondent. 10 March 2026
Biotechnology
The recent news flow at Dewpoint Therapeutics—the firm making condensate biology a clinical reality—has been striking in its volume and significance. 10 March 2026
Biotechnology
February 2026 delivered significant signals across the rare disease ecosystem, spanning regulatory approvals, legislative incentives, clinical trial outcomes, emerging designations, and safety reviews. Below is a summary of the most impactful developments. 2 March 2026
Pharmaceutical
India’s diabetes treatment market is on the cusp of a seismic shift. With the patent on semaglutide expiring on March 21, 2026, several domestic pharma companies are preparing to launch generic versions of the blockbuster drug, even as Abbott has announced a strategic partnership with Novo Nordisk to commercialize a second semaglutide brand in the country, reports The Pharma Letter’s India correspondent. 2 March 2026
One to Watch Companies
One to watch
A privately-held French biotech advancing a clinical pipeline of gamma delta T-cell-focused antibodies for cancer and autoimmune diseases.
One to watch
MaaT Pharma, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases.
One to watch
Privately-held GAIA is focused on the development of evidence-based, safe and accessible AI-powered digital therapeutics (DTx) that help patients restore and maintain their mental and physical health.
One to watch
Exsilio Therapeutics is developing genomic medicines that can be delivered in lipid nanoparticles to durably and safely treat a broad range of diseases, including genetic diseases, cancer, and autoimmune conditions.
Boardroom
Biotechnology
Swiss biotech Idorsia (SIX: IDIA) said chief executive Srishti Gupta has stepped down from her role and from the company’s board, less than a year after taking the helm. Founder and chairman Jean-Paul Clozel will take charge of day-to-day operations as interim CEO while the board searches for a permanent successor. 16 March 2026
Pharmaceutical
Important research news last week included Vertex announcing positive Phase III results for its povetacicept in immunoglobulin A nephropathy. And, BridgeBio reported positive Phase III results for BBP-418 in muscular dystrophy. Also of note, German biotech BioNTech revealed that its co-founders were planning to leave the company, along with 2025 financial results. 15 March 2026
Biotechnology
Israeli clinical-stage drug developer Purple Biotech today announced that its chief executive, Gil Efron, will step down from his role as CEO effective August 2026. 13 March 2026
Pharmaceutical
Ratio Therapeutics, a US pharma company developing radiopharmaceuticals for cancer treatment and monitoring, has announced the appointment of Colin Hayward as chief medical officer (CMO). 13 March 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze